Recently, Friedman et al. reported that cenicriviroc, a dual antagonist of CCR2 and CCR5, showed a significant benefit in patients with non-alcoholic steatohepatitis with liver fibrosis65. Here, CCR2 is linked to metabolic dysfunction-associated steatohepatitis.